CROWN
Lorlatinib in Untreated ALK-Positive Advanced NSCLC
Paciente / Población Intervención / Exposición Comparación Desenlace
In 296 patients with untreated advanced ALK-positive NSCLC, lorlatinib improved progression-free survival and intracranial response compared with crizotinib.
N
296
Diseño
Open-label RCT
Desenlace
BICR-assessed PFS
Relevancia
2
Resultado12-mo PFS 78% vs 39% (HR 0.28, 95% CI 0.19–0.41, P<0.001). Intracranial ORR 82% vs 23% in patients with measurable baseline brain mets.
Shaw AT, et al. N Engl J Med. 2020;383(21):2018-2029; Solomon BJ, et al. J Clin Oncol. 2024;42(29):3400-3409. 10.1056/NEJMoa2027187
Discusión y crítica
Largest PFS effect ever reported in 1L ALK+ NSCLC; intracranial activity is the new benchmark.